Triple–hormone-receptor agonist
Retatrutide
Triple–hormone-receptor agonist. Supplied for laboratory research use only.
- Triple receptor agonist: GLP-1, GIP, and glucagon
- Phase 2: 24.2% mean body-weight reduction at 12mg, n=338
- Phase 3 (TRIUMPH) ongoing; no peer-reviewed result yet
- Supplied for laboratory research use only. Not for human or veterinary use.
90-Day Money-Back Guarantee
Every order is covered for ninety days from delivery. If you decide against it inside that window, contact us and we will refund the purchase price.
Research use only. Not for human or veterinary use or consumption. This product is not approved by the FDA and is not intended to diagnose, treat, cure or prevent any disease.
What it is
Development status
Retatrutide is an investigational compound and is not approved by the FDA for any indication. It is in Phase 3 clinical trials under the TRIUMPH programme.
Up to 10 registered trials. No Phase 3 result has been published in a peer-reviewed journal. Lilly has stated it intends to file a BLA with the FDA in Q1 2027.
Shipping & returns
Where this sits
One receptor. Then two. This one works on three.
Ozempic and Wegovy are semaglutide. It works on one receptor. Mounjaro and Zepbound are tirzepatide — that one works on two. Retatrutide works on three. It comes from Eli Lilly, the same company behind Mounjaro, and it is the newest of the three by some distance.
What ships
What actually turns up at your door.
A single vial holding a dry white powder. No box, no leaflet, no instructions — because no regulator anywhere has approved this compound yet, so there is no approved label to print. It is supplied for laboratory research use only, not for human or veterinary use.
What exists instead
We would rather show you the evidence than sell you a promise.
Most places selling this tell you what it does. We would rather show you what was actually measured. One trial has been through proper independent review and was published in the New England Journal of Medicine. Ten more are running, and those have announced results but have not been independently reviewed yet. Those are two very different things, and this page keeps them apart.
Mechanism
Two of them turn the tap down. The third opens the drain.
Two of the three receptors handle appetite. They slow the stomach down and quiet the hunger signal — that is the whole of how semaglutide works, and most of how tirzepatide works. The third receptor, glucagon, does something the other two do not: it raises how much energy the body burns at rest. So the first two turn the tap down. The third one opens the drain. That is the entire difference between this molecule and the two that came before it.
The specifics
The details, if you want them.
Development
Where it is up to.
In Phase 3 clinical development (TRIUMPH programme, 10 registered trials). No Phase 3 result has been published in a peer-reviewed journal yet.
The trial record
What the trial actually measured.
338 adults with obesity, or overweight with a related condition, given one injection a week for 48 weeks. The bars show average body-weight change at 24 weeks. By the end of the trial the 8 mg group was down 22.8% and the 12 mg group 24.2% — the low-dose groups were never published for that timepoint, so they are not shown. The part most sellers leave out: 73–94% of people on retatrutide reported a side effect, against 70% on placebo — mostly nausea, diarrhoea and vomiting, and worse at higher doses. Enough of them stopped that dropout ran from 6% on the lowest dose to 16% on the highest, against nobody on placebo. Those numbers came from the same 338 people as the ones above.
Topline only — not peer-reviewed
The newer numbers are bigger. They are also less checked.
Everything below is Eli Lilly announcing its own results before anyone independent has checked them. Companies do not usually announce their disappointing numbers this way. Treat it as weaker evidence than the trial above, because it is.
- TRIUMPH‑1 — adults with obesity or overweight, without type 2 diabetes. 80 weeks, 12 mg: 28.3% mean body-weight reduction. 65.3% of that arm reached a BMI under 30.
- TRIUMPH‑4 — obesity or overweight with knee osteoarthritis. 68 weeks, 12 mg: 28.7%.
- TRIUMPH‑2 — participants with type 2 diabetes. 80 weeks: up to 20.8%, with HbA1c down by up to 1.6 percentage points.
Regulatory status
Nobody has approved this. Not anywhere, not for anything.
Not approved. Not by the FDA, not in Europe, not in the UK, not in Australia — nowhere, for anything. Lilly has not even filed the application yet; it says it will in early 2027. Approval reviews run about a year, so if it is approved at all, that is late 2027 or 2028. Anyone telling you it is nearly approved is guessing.
There is more, and it is not in our favour. The FDA has said outright that retatrutide cannot be used in compounding under federal law, and it has sent warning letters naming this compound specifically — to GLP-1 Solution in September 2025 and to Gram Peptides in March 2026 — describing it as an unapproved new drug. There is no lawful route to this molecule in the United States outside research supply, because there is no approved form of it at all.
What ships
The good numbers and the bad ones, on the same page.
That is the whole record, good half and bad half, in one place. We have not hidden the side-effect numbers underneath the weight numbers, because they came out of the same 338 people and printing one without the other would be lying by layout. If you would rather read the source than our summary of it, the trial is NEJMoa2301972 and the rest are on ClinicalTrials.gov under LY3437943.
Supplied for laboratory research use only — not for human or veterinary use.
Questions
The questions people actually ask.
How do I check the vial matches its certificate?
How is it shipped, and does it need cold chain?
How should an unopened vial be stored?
What if it arrives damaged or the contents look wrong?
What is the refund policy?
Is retatrutide approved by the FDA?
